HCAT (Health Catalyst, Inc Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by HCAT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Simeon Kohl | Chief Executive Officer | MIXED | — | — |
| 2026-09-11 | Benjamin Albert | CEO | F | — | — |
| 2026-09-03 | Julie Larson-Green | Director | A | — | — |
| 2026-09-03 | Benjamin Landry | General Counsel | F | — | — |
| 2026-09-03 | Jason Alger | Chief Financial Officer | F | — | — |
| 2026-09-03 | Benjamin Albert | CEO | F | — | — |
| 2026-07-20 | Julie Larson-Green | Director | A | — | — |
| 2026-07-20 | Justin Spencer | Director | A | — | — |
| 2026-07-20 | Steven H Nelson | Director | A | — | — |
| 2026-07-20 | Green Jill Hoggard | Director | A | — | — |
| 2026-06-15 | Benjamin Albert | CEO | F | — | — |
| 2026-06-03 | Jason Alger | Chief Financial Officer | F | — | — |
| 2026-06-03 | Benjamin Albert | CEO | F | — | — |
| 2026-06-03 | Benjamin Landry | General Counsel | F | — | — |
| 2026-06-03 | Linda Llewelyn | Chief People Officer | F | — | — |
| 2026-06-03 | Julie Larson-Green | Director | A | — | — |
| 2026-05-04 | Steven H Nelson | Director | A | — | — |
| 2026-05-01 | Benjamin Albert | CEO | MIXED | — | — |
| 2026-03-13 | Benjamin Albert | CEO | F | — | — |
| 2026-03-05 | Jason Alger | Chief Financial Officer | F | — | — |
| 2026-03-05 | Julie Larson-Green | Director | A | — | — |
| 2026-03-05 | Benjamin Albert | CEO | F | — | — |
| 2026-03-05 | Linda Llewelyn | Chief People Officer | F | — | — |
| 2026-03-05 | Benjamin Landry | General Counsel | F | — | — |
| 2026-02-27 | Linda Llewelyn | Chief People Officer | MIXED | — | — |
| 2026-02-27 | Benjamin Landry | General Counsel | MIXED | — | — |
| 2026-02-27 | Jason Alger | Chief Financial Officer | MIXED | — | — |
| 2026-02-27 | Benjamin Albert | CEO | MIXED | — | — |
| 2026-02-19 | Duncan Gallagher | Director | A | — | — |
| 2025-12-09 | Julie Larson-Green | Director | Sell | — | — |
| 2025-12-09 | Benjamin Landry | General Counsel | Sell | — | — |
| 2025-12-03 | Linda Llewelyn | Chief People Officer | F | — | — |
| 2025-12-03 | Daniel D. Burton | Chief Executive Officer | F | — | — |
| 2025-12-03 | Duncan Gallagher | Director | A | — | — |
| 2025-12-03 | Kevin Lee Freeman | Chief Commercial Officer | F | — | — |
| 2025-12-03 | Benjamin Landry | General Counsel | F | — | — |
| 2025-12-03 | Julie Larson-Green | Director | A | — | — |
| 2025-12-03 | Jason Alger | Chief Financial Officer | F | — | — |
| 2025-09-26 | Benjamin Albert | President and COO | A | — | — |
| 2025-09-09 | Benjamin Landry | General Counsel | Sell | — | — |
| 2025-09-05 | Duncan Gallagher | Director | A | — | — |
| 2025-09-05 | Julie Larson-Green | Director | A | — | — |
| 2025-09-04 | Jason Alger | Chief Financial Officer | F | — | — |
| 2025-09-04 | Daniel D. Burton | Chief Executive Officer | F | — | — |
| 2025-09-04 | Daniel LeSueur | Chief Operating Officer | F | — | — |
| 2025-09-04 | Benjamin Landry | General Counsel | F | — | — |
| 2025-09-04 | Linda Llewelyn | Chief People Officer | F | — | — |
| 2025-09-04 | David Coy Ross | Chief Tech & Product Officer | F | — | — |
| 2025-09-04 | Kevin Lee Freeman | Chief Commercial Officer | F | — | — |
| 2025-09-03 | Justin Spencer | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,704,243 | — |
| — | 10%+ Owner | 3,545,211 | — |
| — | 10%+ Owner | 3,504,304 | — |
| — | Chief Executive Officer | 2,856,385 | — |
| — | Director | 1,755,647 | — |
| — | Chief Executive Officer | 1,393,099 | — |
| — | CEO | 1,388,406 | — |
| — | Chief Financial Officer | 704,867 | — |
| — | Chief Commercial Officer | 358,686 | — |
| — | General Counsel | 351,372 | — |
| — | Chief People Officer | 321,132 | — |
| — | Director | 287,189 | — |
| — | President | 265,025 | — |
| — | Director | 235,499 | — |
| — | Chief Financial Officer | 219,849 | — |
| — | Chief Operating Officer | 204,880 | — |
| — | Chief Tech & Product Officer | 204,219 | — |
| — | Chief Operating Officer | 198,367 | — |
| — | Director | 185,101 | — |
| — | Director | 170,719 | — |
| — | Chief Technology Officer | 164,484 | — |
| — | Director | 149,263 | — |
| — | Director | 144,628 | — |
| — | General Counsel | 133,097 | — |
| — | Director | 132,023 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HCAT quote page; the site-wide leaderboard is on the insider transactions hub.